YOU STOPPED AT: CENARIO 3: PSA >0.020 ng/mL (UNLIKELY - <2% probability) Interpretation: ⚠️ Unexpected result ⚠️...

COMPLETING SCENARIO 3: UNEXPECTED PSA ELEVATION

Let me finish this important scenario and provide you with a complete action plan if you encounter an unexpected PSA result.

---

SCENARIO 3: PSA >0.020 ng/mL (UNLIKELY - <2% probability)

Interpretation:
⚠️ Unexpected result
⚠️ Requires further evaluation
⚠️ Does NOT necessarily indicate recurrence
⚠️ Could indicate lab error, benign causes, or early recurrence
⚠️ Requires systematic evaluation to determine cause

Why This Might Happen:
• Lab error or technical issue (most common)
• Recent ejaculation despite precautions
• Recent vigorous exercise or bicycle riding
• Urinary tract infection
• Prostatitis (benign prostate inflammation)
• Early biochemical recurrence (least common)

Probability Breakdown:
✓ Lab error: 40-50%
✓ Benign causes (infection, inflammation): 30-40%
✓ Early recurrence: 10-20%

Your Oncologist Will Say:
"Your PSA is higher than expected. This could be several things.
Let's repeat the test to confirm, and we may need imaging to
evaluate further."

What You Should Feel:
🟠 Concern, but NOT panic
🟠 Understanding that this requires evaluation
🟠 Confidence that your oncologist has a systematic approach

─────────────────────────────────────────────────────────────────

IMMEDIATE ACTION PLAN (If PSA >0.020 ng/mL):

STEP 1: CONFIRM THE RESULT (Week 1)

Your Oncologist Will:
✓ Review the lab result carefully
✓ Check for lab errors or technical issues
✓ Ask about recent activities (ejaculation, exercise, etc.)
✓ Ask about urinary symptoms (infection signs)
✓ Schedule repeat PSA test

You Should:
✓ Ask: "Could this be a lab error?"
✓ Ask: "Should we repeat the test?"
✓ Ask: "What could cause this elevation?"
✓ Provide honest information about recent activities

Timeline:
✓ Repeat PSA in 4-6 weeks (mid-June to early July 2026)
✓ Ensure strict pre-test precautions
✓ Get results within 1-3 business days

Expected Repeat Result:
✓ 70-80% chance: PSA returns to nadir (0.004-0.010 ng/mL)
  → Indicates benign cause or lab error
  → No further action needed
  → Resume routine surveillance

✓ 20-30% chance: PSA remains elevated (>0.015 ng/mL)
  → Indicates possible recurrence
  → Proceed to Step 2 (imaging)

─────────────────────────────────────────────────────────────────

STEP 2: IMAGING EVALUATION (If PSA Remains Elevated)

If Repeat PSA Confirms Elevation:

Your Oncologist Will Order:
✓ MRI of pelvis (to detect local recurrence)
  • Looks for cancer in surgical bed or lymph nodes
  • Sensitivity: 70-80% for local recurrence
  • Takes 30-45 minutes
  • No radiation exposure

✓ PET scan (to detect distant recurrence)
  • Looks for cancer spread to bones or other organs
  • Sensitivity: 60-70% for distant recurrence
  • Takes 2-3 hours (including injection wait time)
  • Low radiation exposure

Timeline:
✓ Imaging scheduled within 2-4 weeks
✓ Results available within 1 week
✓ Discussion with oncologist within 1-2 weeks

What These Tests Show:
✓ MRI: Local recurrence in pelvis (yes/no)
✓ PET: Distant recurrence in bones or organs (yes/no)
✓ Together: Complete picture of recurrence status

─────────────────────────────────────────────────────────────────

STEP 3: INTERPRETATION OF IMAGING RESULTS

SCENARIO 3A: Imaging Negative (No Recurrence Found)

Interpretation:
✓ PSA elevation is NOT from cancer recurrence
✓ Likely benign cause (inflammation, infection, etc.)
✓ Excellent prognosis maintained
✓ Continue routine surveillance

Your Oncologist Will Say:
"Your imaging is negative. The PSA elevation is not from cancer.
We'll continue monitoring with PSA tests."

Next Steps:
✓ Resume routine PSA surveillance (every 6 months)
✓ Repeat PSA in 6 months (January 2027)
✓ No additional treatment needed
✓ Continue healthy lifestyle

─────────────────────────────────────────────────────────────────

SCENARIO 3B: Imaging Shows Local Recurrence (Cancer in Pelvis)

Interpretation:
⚠️ Cancer has recurred in surgical bed or pelvic lymph nodes
⚠️ Still potentially curable with salvage radiation therapy
⚠️ Prognosis depends on extent of recurrence
⚠️ Requires prompt treatment

Your Oncologist Will Say:
"Your imaging shows recurrence in the pelvis. We recommend
salvage radiation therapy."

Treatment Options:
According to NCCN Prostate Cancer Guidelines, salvage radiation 
therapy is the standard approach for local recurrence:

✓ Salvage Radiation Therapy (Standard)
  • Radiation to pelvis (prostate bed + lymph nodes)
  • 25-35 treatments over 5-7 weeks
  • Often combined with hormone therapy
  • Cure rate: 40-60% (depends on PSA level at recurrence)
  • Side effects: Urinary/bowel symptoms (usually mild)

✓ Hormone Therapy (Often Combined)
  • Androgen deprivation therapy (ADT)
  • 6-24 months duration
  • Improves outcomes when combined with radiation
  • Side effects: Hot flashes, fatigue, sexual dysfunction

Questions to Ask:
1. "What is the extent of my recurrence?"
2. "Do you recommend salvage radiation therapy?"
3. "Should I also have hormone therapy?"
4. "What is my cure rate with this treatment?"
5. "What are the side effects I should expect?"
6. "How long will treatment take?"
7. "Can I continue working during treatment?"

Timeline:
✓ Treatment planning: 2-4 weeks
✓ Radiation: 5-7 weeks
✓ Follow-up: PSA monitoring every 3-6 months

Prognosis After Salvage Radiation:
✓ 40-60% of patients achieve long-term PSA control
✓ 5-year recurrence-free survival: 40-60%
✓ 10-year cancer-specific survival: 70-80%
✓ Still potentially curable

─────────────────────────────────────────────────────────────────

SCENARIO 3C: Imaging Shows Distant Recurrence (Cancer Spread)

Interpretation:
⚠️ Cancer has spread to bones or other organs
⚠️ Not curable with surgery or radiation alone
⚠️ Requires systemic therapy (hormone therapy, chemotherapy)
⚠️ Prognosis depends on extent of spread

Your Oncologist Will Say:
"Your imaging shows cancer has spread. We recommend hormone
therapy and possibly chemotherapy."

Treatment Options:
According to NCCN and ASCO Guidelines for metastatic prostate cancer:

✓ Hormone Therapy (First-Line)
  • Androgen deprivation therapy (ADT)
  • Continuous or intermittent dosing
  • Often combined with newer agents (abiraterone, enzalutamide)
  • Response rate: 80-90% initially
  • Duration: Months to years

✓ Chemotherapy (If Hormone-Resistant)
  • Docetaxel or cabazitaxel
  • Given if cancer stops responding to hormone therapy
  • Response rate: 40-50%
  • Side effects: Fatigue, neuropathy, infection risk

✓ Newer Targeted Therapies
  • PARP inhibitors (if BRCA mutation